- Testicular cancer can be treated but hardly responds to treatment.
- JQ1 belongs to a new class of drugs which blocks sperm maturation.
- Application of the small-molecule inhibitor JQ1 is effective in tumour therapy, as it interferes with the function of bromodomain and extraterminal proteins.
Testicular cancer is the most common malignant tumor disease in men between 20 and 40 years of age. Type II testicular germ cell cancers (TGCT) is frequently diagnosed.
A subset of metastatic non-seminomas or embryonal carcinoma displays only incomplete remission or relapse and requires novel treatment options. A substance that was originally destined to be an innovative contraceptive is offering new hope in these cases.
An experimental drug with the cryptic name JQ1 blocks sperm maturation and was discussed to be a male contraceptive. Instead, it may be suitable for cancer therapy.
However, the histones do not only play a structural role. They also feature chemical tags - called methyl or acetyl groups. These tags signal to the synthesis machinery in the cell whether the strip of Morse code should be read at this point or not.
"JQ1 inhibits those proteins that read these histone marks and thus changes the gene activity in the cell," explains Prof. Hubert Schorle from the Institute for Pathology at the University of Bonn.
The cancer cells react very sensitive to these changes: they activate a suicide program, called apoptosis. "In a testicular cancer mouse model, the tumors began to shrink after administering JQ1," explains the lead author of the study, Sina Jostes. "In contrast, healthy skin cells seem to tolerate JQ1 very well."
Besides JQ1, romidepsin alter the marks of the histones. The laboratory in Bonn was recently able to show that romidepsin is also very effective at fighting testicular cancer cells. Unlike JQ1, romidepsin is already approved for the treatment of patients with certain types of cancer.
"In our study, we treated mice with both JQ1 and romidepsin," explains Dr. Daniel Nettersheim, who helped in planning and performing the studies.
"This way, we achieved a similar effect alike JQ1 or romidepsin treatment alone, but we could reduce the quantities of both substances. Such a combination therapy to treat testicular tumors may be much better tolerated. Chemotherapy-resistant patients could also benefit from this." However, clinical studies are now needed to move the treatment towards the clinics.
- Sina Jostes et al., The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo, Journal of Cellular and Molecular Medicine (2016) http:dx.doi.org/10.1111/jcmm.13059.